It has been shown previously that protein kinase A (PKA) maintains Xenopus oocytes arrested at G2, at least in part by preventing c-mos translation, but how PKA controls c-mos translation is not known. Using microinjection of recombinant c-mos, which still activates MAP kinase in the presence of active PKA, we have found that PKA does not exert any eect on translation of endogenous c-mos if MAP kinase is ®rst activated. Even though they accumulate c-mos and contain MAP kinase activity as high as control oocytes, oocytes do not exit G2 in the presence of active PKA. These results are discussed in connection with recent ®ndings on regulation of c-raf activity.
Introduction
Our present knowledge of cell cycle control is largely derived from convergent studies using yeast genetics and oocyte biochemistry (reviewed in Nurse, 1990; Doree and Galas, 1994; Nigg, 1995) . In 1971, Xenopus oocytes provided the ®rst functional assay to de®ne two dominant factors that were named MPF (maturation-promoting factor) and CSF (cytostatic factor), respectively speci®cally responsible for the G2 to M-phase transition of the cell cycle in all eukaryotic cells and for arrest at meiotic metaphase II in vertebrate oocytes (Masui and Markert, 1971; Kishimoto et al., 1982) . Both factors were identi®ed in 1989, MPF as a heterodimeric complex comprising one molecule of cdc2 and one molecule of cyclin B (LabbeÂ et al., 1989 in star®sh, and Gautier et al., 1990 in Xenopus) and CSF as the product of the protooncogene c-mos (Sagata et al., 1989) .
In the assay for MPF activity, fully-grown Xenopus oocytes arrested at G2 in the ®rst meiotic cell cycle were treated with progesterone, which induced exit from G2 and entry into M-phase. Cytoplasm of oocytes at M-phase was shown to contain a factor able to trigger the G2 to M-phase transition in recipient oocytes in the absence of hormonal treatment. Surprisingly, how progesterone acts to produce MPF activity is still unknown even though stimulation of c-mos translation has been demonstrated to be an essential relay between hormonal stimulation and MPF activation. The c-mos protein kinase has been shown to directly phosphorylate MAP kinase kinase (Nebreda et al., 1993; Posada et al., 1993; Shibuya et al., 1996) , resulting in MAP kinase activation, itself absolutely required in Xenopus for hormone-stimulated oocytes to convert MPF from an inactive into an active form (reviewed in Sagata, 1997) . Another important early result was that inactivation of protein kinase A (PKA) through microinjection of its regulatory subunit or its speci®c thermostable inhibitor mimics progesterone treatment in Xenopus oocytes (Maller and Krebs, 1977) . As progesterone was also reported to trigger an initial drop of cAMP in Xenopus oocytes (Speaker and Butcher, 1977) , this led to the view that progesterone acts through inactivation of protein kinase A, leading to diminished phosphorylation of an (unidenti®ed) inhibitory protein (reviewed in Maller, 1983) which would in its PKA-phosphorylated form suppress, directly or indirectly, c-mos translation (Sagata, 1997) . Consistent with this view, hormonestimulated oocytes microinjected with the catalytic subunit of PKA (PKAc) or treated with known elevators of intracellular cAMP, do not synthesize cmos (Matten et al., 1994) .
However, how PKA negatively controls c-mos translation has still not been elucidated, even though control of c-mos translation in oocytes has been the subject of several recent investigations (Sheets et al., 1994 (Sheets et al., , 1995 Gebauer et al., 1994) . The aim of the present work was to investigate the mechanism that allows PKA to suppress c-mos translation. Unexpectedly, we found that PKA does not exert any inhibitory eect on c-mos translation, provided oocytes are ®rst allowed to activate MAPK. This leads us to reconsider potential inhibitory targets for PKA in maintaining vertebrate oocytes arrested at G2.
Results

PKA suppresses MPF activation but does not reduce the extent of MAP kinase activation in oocytes microinjected with recombinant c-mos
Microinjection of PKAc or treatments that elevate intracellular cAMP, including cholera toxin and 3-isobutyl-1-methyl xanthine (IBMX), have been shown in many laboratories to suppress MPF activation and germinal vesicle breakdown (GVBD) induced by both progesterone and recombinant c-mos (Maller and Krebs, 1977; Godeau et al., 1978; Huchon and Ozon, 1979; Rime et al., 1992; Daar et al., 1993) . Furthermore, microinjection of PKAc has been shown to prevent progesterone from activating MAP kinase (Matten et al., 1994) . However, con¯icting results were obtained when the eect of PKA on c-mos-induced activation of MAPK was investigated. Using a cell-free system prepared from Xenopus oocytes, Van Renterghem et al. (1994) reported that pretreatment of extracts with PKAc had no eect on the ability of cmos to activate MAPK, suggesting that both the direct activation of MAPKK by c-mos and the activation of MAPK by MAPKK are insensitive to PKA. In contrast, Matten et al. (1994) , using microinjection into oocytes, reported that microinjected PKAc decreased activation of MAPK by microinjected cmos to 50% of the control level.
In the ®rst report by Van Renterghem et al. (1994) PKAc was used at the ®nal concentration of 1.5 mM, which compares well with the endogenous level of PKA in stage VI oocytes (about 1 mM: Maller and Krebs, 1977) . However, protein synthesis is de®cient in diluted oocyte extracts, thus the possible eect of PKAc on synthesis of endogenous c-mos was not taken into account. In the second report by Matten et al. (1994) the amount of microinjected PKAc was as high as six nanograms per oocyte, which corresponds to an intracellular concentration of about 200 mM. As emphasized by the authors themselves,`it is possible to envision a coordinated localization of PKAc and cmos during the maturation process that would modulate the eects of their kinase activities'. Results could thus have been biased by the use of a too high level of microinjected PKAc. This led us to reconsider the eect of PKA on c-mos activation of MAPK.
In the following experiments, we investigated the eects of activating endogenous PKA, by external treatment with 1 mM IBMX, on H1 kinase activation, induction of GVBD, and the extent of MAPK activation in intact oocytes treated with progesterone or microinjected with 10 ng of recombinant c-mos.
As expected and previously reported, IBMX treatment suppressed H1 kinase activation and GVBD in oocytes treated with progesterone or microinjected with c-mos (Figure 1a) . Suppression of H1 kinase activity was reversed by transferring oocytes into IBMX-free medium, and microinjection of the regulatory subunit of PKA accelerated this process (not shown).
To evaluate the eect of IBMX on MAPK activation by progesterone treatment or c-mos microinjection, aliquots of extracts used for determination of H1 kinase activities were analysed by SDS ± PAGE and monitored after renaturation for in-gel MBP kinase activity of MAP kinase. As shown in Figure 1b , IBMX abolished activation of MAPK by progesterone, but did not reduce the extent of MAPK activation due to c-mos microinjection. This result was con®rmed by immunoblotting with anti-MAPK antibodies ( Figure  1c ): electrophoretic mobility of MAPK did not increase following IBMX treatment in c-mos microinjected oocytes, consistent with the view that MAPK did not undergo dephosphorylation and inactivation in the above experiments.
PKA does not prevent recombinant c-mos from stimulating the translation of endogenous c-mos
To investigate the eect of PKA on c-mos translation triggered by progesterone or microinjection of recombinant c-mos, immature oocytes were ®rst treated with 1 mM IBMX, or not (controls). They were then either S-methionine, were kept in the presence or absence of IBMX and treated with progesterone or microinjected with recombinant c-mos. After 4 h, when oocytes non-treated with IBMX had undergone GVBD, c-mos immunoprecipitates were Western-blotted to localize c-mos, and c.p.m. in stimulated with progesterone, or microinjected with recombinant c-mos. Extracts were prepared after control oocytes treated with progesterone only had reached metaphase II, 8 h after hormonal stimulation or c-mos microinjection. At this time, all microinjected oocytes incubated in the absence of IBMX had matured, while the others remained arrested with an intact germinal vesicle. Oocyte extracts were then prepared and analysed by immunoblotting for c-mos content. As expected, IBMX was found to suppress cmos accumulation in progesterone-treated oocytes ( Figure 2a ). In contrast, it was not found to suppress the accumulation of a 39 kDa protein, triggered by microinjection of recombinant c-mos and identi®ed as newly synthesized c-mos by virtue of its cross-reactivity to anti-mos antibodies and its suppression by cycloheximide treatment. We checked that this was not a proteolytic fragment of the infected recombinant protein by injecting radiolabelled recombinant c-mos fusion protein, produced by growing E. coli in the presence of + tail lengths to be compared, autoradiograms were scanned and normalized to identical maximal optical densities. Lengths of RNAs (nt: nucleotides) were estimated by running in the same gel radiolabelled plasmid inserts of known sizes, including the plasmid encoding the 177 bp 3'-UTR, whose migration was identical to that of the corresponding RNA absence of IBMX. After 4 h, when oocytes non-treated with IBMX had undergo GVBD, c-mos was immunoprecipitated from lysates and monitored by autoradiography for [ 35 S]methionine content. As shown in Figure  2b , IBMX severely depressed c-mos translation in progesterone-treated oocytes, but it had no such effect in oocytes microinjected with the recombinant protein.
To con®rm that PKA does not exert any inhibitory eect on c-mos translation in oocytes microinjected with recombinant c-mos, a subset of the oocytes receiving recombinant c-mos or progesterone were microinjected with 0.2 ng of PKAc in the absence of IBMX. As also shown in Figure 2a , no dierence was observed when compared to IBMX treatment: PKAc readily suppressed GVBD and progesterone-dependent translation of c-mos, but did not signi®cantly reduce the extent of c-mos translation and accumulation in oocytes microinjected with recombinant c-mos.
Polyadenylation of c-mos mRNA is known to be essential for c-mos translation and meiotic maturation in progesterone-treated oocytes (Sheets et al., 1994 (Sheets et al., , 1995 Gebauer et al., 1994) . Thus, the above results suggested that PKA activation may have dierential eects on polyadenylation of c-mos RNA in oocytes treated with progesterone or microinjected with recombinant c-mos. To investigate this point, we prepared labelled RNAs in vitro that contained the terminal 177 nucleotides of c-mos (from the start of the poly(A) + tail) and injected these into the cytoplasm of oocytes. Progesterone or the recombinant c-mos protein were added or microinjected to initiate maturation in the presence or absence of 1 mM IBMX. After maturation (in the absence of IBMX), RNA was extracted from the oocytes and the increase in the length of the probe was estimated by electrophoresis and autoradiography. This increase has been shown previously to correspond to the length of the poly(A) + tail added within the oocyte to the microinjected RNA (Sheets et al., 1994) . As shown in Figure 3 , the scattered distribution of poly (A) + tails was found to peak between 40 and 50 nucleotides in progesterone-treated oocytes, in good agreement with previous results (Sheets et al., 1994) and even slightly higher (between 60 and 70 nucleotides) in oocytes induced to mature through microinjection of recombinant c-mos. As expected, we found that IBMX reduced poly(A) + extension in progesterone-stimulated oocytes. In contrast, it did not reduce the length of the poly(A) + tail added to the microinjected 32 P-labelled 3'-UTR in oocytes microinjected with the recombinant c-mos protein.
As microinjection of the CL100 phosphatase, which inactivates MAPK (Keyse and Emslie, 1992) , inhibits progesterone-dependent synthesis and accumulation of c-mos (Gotoh et al., 1995) , a likely interpretation of the above experiments is that down-regulation of PKA is required for progesterone to activate MAPK, but once Figure 4 The CL100 MAPK phosphate strongly depresses MAPK activation and c-mos translation in oocytes microinjected with the recombinant c-mos protein. Oocytes were microinjected (+) or not (7) with mRNAs encoding CL100, and after overnight incubation, microinjected with pMal-c-mos. At the indicated times (hours) after the last microinjection, oocytes were homogenized and analysed by in-gel kinase assay for determination of MAPK activity (a) or Western blot for translation and accumulation of endogenous p39 c-mos (b) . GVBD occurred about 6 h after microinjection of pmal-c-mos in 100% of the oocytes that were not microinjected with CL100 mRNAs. It did not occur in oocytes microinjected with CL100 MAPK is activated, PKA does not exert any inhibition on c-mos translation. As similar amounts of newly synthesized c-mos were detected in the absence or presence of IBMX, yet IBMX suppressed cyclin B-cdc2 kinase activation, this latter is likely dispensable, unlike MAPK, for full-activation of c-mos translation. To con®rm that MAPK activation is required for c-mos translation, we ®rst microinjected mRNAs encoding CL100 and after the MAPK phosphatase had accumulated, we microinjected the recombinant c-mos protein. As shown in Figure 4 , control oocytes readily activated MAPK, accumulated p39 c-mos and underwent GVBD. In contrast, translation and accumulation of p39 c-mos was severely depressed, and GVBD did not occur, in oocytes expressing CL100, that hardly activated MAPK.
Besides c-mos, translation of several other proteins involved in cell cycle control is stimulated following progesterone stimulation of Xenopus oocytes. This includes cdk2, which, unlike c-mos, is already expressed in G2-arrested oocytes (Gabrielli et al., 1993; Rempel et al., 1995) . To investigate whether MAPK activation exerts a similar PKA-independent eect on cdk2 translation, as it does on c-mos translation, immunoblots previously used for monitoring c-mos accumulation ( Figure 2 ) were dehybridized and used for detection of cdk2. As shown in Figure 5 , progesterone increased the level of cdk2 and this increase was suppressed by IBMX treatment or PKAc microinjection. Cdk2 level was also somewhat elevated in oocytes microinjected with c-mos, and this elevation was not suppressed by PKA. However, the level of cdk2 increased to a lower extent in c-mos-microinjected than it did in progesterone-stimulated oocytes, contrasting with the higher accumulation of endogenous cmos in the ®rst than in the second category of oocytes. This may indicate that MAPK activation is sucient for full activation of c-mos translation, but possibly not for full translational activation of cdk2.
Discussion
Twenty years after the demonstration (Maller and Krebs, 1977) that PKA is, at least in part responsible for arrest at the G2/prophase boundary of the ®rst meiotic cell cycle of vertebrate oocytes, its target(s) in exerting this inhibitory function have still not been identi®ed. Recently, it was proposed that PKA may have pleiotropic eects and inhibit oocyte maturation at multiple points (Matten et al., 1994; Rime et al., 1994) . One of these eects was proposed to be the inhibition of endogenous c-mos synthesis, another eect the suppression of cdc25 activation. As microinjection of PKAc at levels that block progesteroneinduced translation of endogenous c-mos did not prevent injected c-mos from activating MAP kinase (Matten et al., 1994) , and MAPK activity is required for c-mos translation in Xenopus oocytes (Gotoh et al., 1995) , it was proposed that PKA may inhibit c-mos synthesis at a point downstream of MAPK, perhaps between MAPK and the polyadenylation apparatus of the translation initiation complex (Matten et al., 1996) .
In the present work, we con®rm that PKA does not prevent MAPK activation following c-mos microinjection. However, we ®nd that PKA does not exert any inhibitory eect on c-mos synthesis and accumulation if oocytes are allowed to activate MAPK. This raises the possibility that PKA may in fact not inhibit oocyte maturation at multiple points, but rather exert its inhibitory function by phosphorylating a single target. Speci®cally, we ®nd that, even though microinjection of PKAc or IBMX treatment suppresses progesterone-dependent translation of c-mos, PKA does not suppress translation of endogenous cmos in oocytes microinjected with recombinant c-mos. In fact, oocytes in which PKA is maintained at a high level of activity, sucient to suppress progesteronedependent translation of c-mos and meiotic maturation, readily accumulate c-mos at levels comparable to, or even sometimes higher than, those observed in control progesterone-treated oocytes. The most likely interpretation of these results is that c-mos translation does not occur in progesterone-stimulated oocytes prevented from inactivating PKA merely because such oocytes cannot maintain MAPK at a level of activity sucient for c-mos translation.
As G2-arrested oocytes do not contain detectable cmos, the minimal activity of MAPK required for c-mos translation to be triggered in progesterone-stimulated oocytes may depend on c-raf, which is now recognized to be down-regulated by both PKAc and autophosphorylation (Mischak et al., 1996) . We propose (Figure 6 ) that inactivation of PKA upon progesterone stimulation allows transient activation of c-raf and the MAPK cascade, thereby triggering c-mos translation in the short window that precedes autophosphorylation, thus inactivation, of c-raf. This would explain why MAPK does not maintain a high level of activity if progesterone-treated oocytes are treated with inhibitors of protein synthesis or microinjected with anti-sens oligonucleotides directed against c-mos mRNAs, as in either case c-mos would not relay c-raf and maintain the activity of the MAPK cascade.
Even though oocytes microinjected with recombinant c-mos readily synthesize c-mos and stably activate MAPK in the absence of hormonal stimulation, they do not activate cyclin B-cdc2 kinase if prevented from inactivating PKA. This implies that MAPK activation is not sucient to release oocytes from G2. Again, inhibitory phosphorylation of c-raf may possibly be responsible for failure of oocytes to convert cyclin Bcdc2 kinase from its tyrosine-phosphorylated, inactive form (pre-MPF) into active MPF, a transition which requires cdc25 activation, even in the presence of active MAPK. Indeed cdc25 was reported to quantitatively associate with c-raf and possibly 14-3-3 (Conklin et al., 1995) in Xenopus oocytes. As stable activation of c-raf and cdc25 occurs almost synchronously in hormone-stimulated oocytes, and the phosphatase activity of cdc25 can be activated in vitro in a c-raf dependent manner , cdc25 activation may also require c-raf activation in the intact oocyte and be suppressed if oocytes are prevented from down-regulating PKA and releasing c-raf from PKA-dependent inhibition. This would be consistent with the previous report that progesterone, or mRNAs encoding c-mos, both fail to activate MPF in oocytes microinjected with a dominant-negative version of c-raf mutated in its ATP-binding site (Muslin et al., 1993) , as opposed to a dominant-negative version of c-raf mutated at serine 621, which precisely corresponds to the unique site of PKA phosphorylation in c-raf in vivo (Mischak et al., 1996) . Nonetheless, this model ( Figure 6 ) remains speculative, as direct measurement of c-raf activity has not been carried out in Xenopus oocytes. This is because reagents are not yet available that allow immunoprecipitation of Xenopus c-raf and assay of its kinase activity.
Onset of c-mos translation has been shown to depend on increased polyadenylation of its mRNA during maturation of Xenopus oocytes (Sheets et al., 1994 (Sheets et al., , 1995 . Although the precise mechanism by which polyadenylation at the 3' end stimulates translation initiation at the 5' end of the message is unclear, recent studies have shown that in maturing oocytes, 3' poly(A) + addition induces 5' cap ribose methylation, and that prevention of cap ribose methylation dramatically reduces translational activation (Kuge and Richter, 1995) . Two factors involved in regulation of cytoplasmic polyadenylation have been shown to be phosphorylated coincidentally with the onset of c-mos translation in Xenopus oocytes. One is CPEBP, the cytoplasmic polyadenylation element binding protein (Hake and Richter, 1994; Stebbins-Boaz et al., 1996) , the other poly (A) + polymerase (Foukal Colgan et al., 1996) . As both of these proteins can be phosphorylated, at least in vitro, by cyclin B-cdc2 kinase, it has been suggested that cyclin B-cdc2 kinase may regulate their activity. However, no evidence has been provided previously that cytoplasmic polyadenylation is regulated by phosphorylation, although this is clearly a possibility. Our results establish that cyclin B-cdc2 kinase is not involved in onset of c-mos translation, as oocytes prevented from inactivating PKA, which do not activate cyclin B-cdc2 kinase, are able to translate c-mos mRNA as eciently as control stimulated oocytes. In contrast, MAPK activation is required for increased polyadenylation and onset of c-mos translation.
Materials and methods
Preparation and handling of oocytes
Females of Xenopus were obtained from the CNRS breeding center at Montpellier. Full-grown oocytes were prepared free of follicle cells by collagenase treatment in Ca 2+ -free OR2 (Maller and Krebs, 1977) , then transferred in MMR (100 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 0.1 mM EGTA, 5 mM HEPES pH 7.7.) in which all experiments were performed. The volume of microinjected materials was about 40 nl, delivered near the equator of the oocytes. Progesterone was used at 1 mM. IBMX was added 1 h before hormonal stimulation or microinjection. Oocytes were homogenized in a buer ((10 ml/oocyte) containing 50 mM sucrose, 100 mM KCl, 0.1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES pH 7.8. Homogenates were brie¯y centrifuged in a table-top centrifuge for 2 min at 13 000 r.p.m. to remove yolk, and supernatants used for assays.
Plasmids, recombinant proteins and mRNAs
The recombinant catalytic subunit of PKA was obtained from SIGMA. Recombinant c-mos was produced in E. coli as a fusion protein between the maltose-binding protein and Xenopus c-mos (pMal c-mos) from a plasmid kindly given by A Nebreda and T Hunt (Nebreda and Hunt, 1993) . The recombinant protein was produced as a soluble 79 kDa protein that was puri®ed on a amylose-Sepharose matrix according to standard procedures (Maina et al., 1988) .
The cDNA of CL100 MAPK phosphatase, cloned in pET15b expression vector, was a gift of S Keyse (Keyse and Emslie, 1992) . For the in vitro transcription reaction, this plasmid was linearized on XhoI site and synthesis of capped mRNAs was performed with T7 RNA polymerase.
The terminal 177 bp of the 3' untranslated region (3-'UTR) of c-mos was obtained by RT±PCR, using Mos1S (5'-GGATGCTGGGAGTTGTGGG-3') and Mos1R (5'-GACAAATCAATTTCTTTATT-3') primers; the PCR product was cloned in pcDNA3 vector (designated pcDNA3 177 bp c-mos) and sequenced in both strands using T7 sequenase kit (USB). Capped, radiolabelled RNAs for polyadenylation assays were prepared by in vitro transcription of digested pcDNA3 177 bp c-mos using T7 RNA poly-merase in the presence of a 32 P-UTP as described (Fox et al, 1989) .
Antibodies and immunoprecipitation procedure
The polyclonal antibody directed against Xenopus c-mos and MAPK were obtained from Santa Cruz, USA. Western blots were analysed using ECL detection (Amersham). The c-mos antibody was raised against peptide 314 ± 335 within the carboxy terminal domain of Xenopus laevis p39 c-mos . The MAPK antibody was raised against peptide 305 ± 327 of rat Erk1 and recognizes boh Erk1 and Erk2 in all vertebrates tested. The anti-cdk2 polyclonal antibody was made in rabbits immunized against a peptide corresponding to 16 amino acids at the C-terminus of Xenopus cdk2.
Immunoprecipitation of oocyte extracts with the c-mos polyclonal antibody were performed in modi®ed RIPA buer (10 mM NaH 2 PO 4 pH 7.5, 100 mM NaCl, 5 mM EDTA, 1 % Triton X-100, 0.5% deoxycholate, 80 mM b-glycerophosphate, 50 nM NaF, 1 mM DTT). Immunocomplexes were collected on Protein A-Sepharose, boiled in Laemmli buer and analysed by Western blotting on nitrocellulose after SDS ± PAGE.
Kinases activities
Histone H1 kinase activities were assayed according to LabbeÂ et al. (1991) . In gel-MBP kinase assays were performed exactly as described by Shibuya et al. (1992) . Brie¯y, homogenates prepared from single oocytes were run in 15% poyacrylamide gels containing 0.5 mg/ml MBP. After removing SDS by 20% isopropanol and treating gels with 6 M guanidine, proteins were renatured, and gels incubated in the presence of [g-32 P]ATP. After washing thoroughly the gels, they were dried and analysed by autoradiography.
Polyadenylation assay
Oocytes were injected with 50 nl of radiolabelled 177b cmos 3'UTR RNAs and stimulated with progesterone or microinjected with c-mos recombinant protein in presence or absence of IBMX. Total RNAs were extracted from groups of 30 oocytes according to the method developed by Melton and Cortese (1979) . 4 ml of loading buer (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol) were then added and samples resolved on a 4% polyacrylamide gel after heating for 10 min at 708C. Radioactivity was detected by autoradiogaphy and quanti®ed by scanning the autoradiograms.
